SPARQL | HTML Microdata document This HTML5 document contains 29 embedded RDF statements represented using HTML+Microdata notation.
The embedded RDF content will be recognized by any processor of HTML5 Microdata.
Namespace Prefixes
Prefix IRI n6 http://linked.opendata.cz/resource/mesh/concept/ rdfs http://www.w3.org/2000/01/rdf-schema# rdf http://www.w3.org/1999/02/22-rdf-syntax-ns# n5 http://linked.opendata.cz/ontology/mesh/ owl http://www.w3.org/2002/07/owl# nci http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl# n4 http://linked.opendata.cz/resource/ndfrt/ingredient/ xsdh http://www.w3.org/2001/XMLSchema#
Statements
Subject Item nci:C1176
rdf:type
owl:Class
rdfs:label
Olsalazine
rdfs:subClassOf
nci:C257
nci:A5
nci:C66254
nci:A8
nci:C63923
nci:P106
Pharmacologic Substance
Organic Chemical
nci:P108
Olsalazine
nci:P207
C0069454
nci:P210
15722-48-2
nci:P302
Ulcerative colitis
nci:P319
ULS5I8J03O
nci:P322
FDA
nci:P329
41828
nci:P330
41828
nci:P350
C14H10N2O6
nci:P366
Olsalazine
nci:P368
CHEBI:7770
nci:P90
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>3,3'-Dicarboxy-4,4'-dihydroxyazobenzene</n0:term-name><n0:term-group>SN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Azodisalicylate</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>OLSALAZINE</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>FDA</n0:term-source><n0:source-code>ULS5I8J03O</n0:source-code></n0:ComplexTerm>
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>3,3'-Azobis[6-hydroxybenzoic Acid]</n0:term-name><n0:term-group>SN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>3,3'-Azobis[6-hydroxybenzoic Acid]</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>DCP</n0:term-source><n0:source-code>00801</n0:source-code></n0:ComplexTerm>
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Olsalazine</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>C.I. Mordant Yellow 5</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
nci:P97
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A prodrug of mesalamine (5-Aminosalicylic acid; 5-ASA) with anti-inflammatory activity. Unabsorbed olsalazine passes through gastrointestinal tract and is cleaved by azoreductases, produced by microflora in colon, into 2 active molecules of 5-ASA. 5-ASA exerts its anti-inflammatory action locally by inhibiting cyclooxygenase and lipoxygenase activities, thereby reducing the production of prostaglandins and leukotrienes. In addition, mesalamine may act as a scavenger of reactive oxygen free radicals.</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>
nci:code
C1176
owl:sameAs
n4:N0000006231
n5:hasConcept
n6:M0101640